


**Glycobiology and Extracellular Matrices:
Glycoprotein Biosynthesis in a Eukaryote
Lacking the Membrane Protein Rft1**

Jennifer Jelk, Ningguo Gao, Mauro
Serricchio, Aita Signorell, Remo S. Schmidt,
James D. Bangs, Alvaro Acosta-Serrano,
Mark A. Lehrman, Peter Bütikofer and Anant
K. Menon

J. Biol. Chem. 2013, 288:20616-20623.

doi: 10.1074/jbc.M113.479642 originally published online May 28, 2013



Access the most updated version of this article at doi: [10.1074/jbc.M113.479642](https://doi.org/10.1074/jbc.M113.479642)

Find articles, minireviews, Reflections and Classics on similar topics on the [JBC Affinity Sites](http://www.jbc.org/).

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 36 references, 18 of which can be accessed free at
<http://www.jbc.org/content/288/28/20616.full.html#ref-list-1>

Glycoprotein Biosynthesis in a Eukaryote Lacking the Membrane Protein Rft1*

Received for publication, April 22, 2013, and in revised form, May 21, 2013. Published, JBC Papers in Press, May 28, 2013; DOI 10.1074/jbc.M113.479642

Jennifer Jelk^{‡1}, Ningguo Gao^{§1}, Mauro Serricchio^{‡1}, Aita Signorell[¶], Remo S. Schmidt[‡], James D. Bangs^{||}, Alvaro Acosta-Serrano^{**}, Mark A. Lehrman^{§2}, Peter Bütikofer^{‡3}, and Anant K. Menon^{¶4}

From the [‡]Department of Biochemistry, Weill Cornell Medical College, New York, New York 10065, the [¶]Institute of Biochemistry and Molecular Medicine, University of Bern, 3012 Bern, Switzerland, the [§]Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, the ^{||}Department of Microbiology and Immunology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York 14214, and the ^{**}Parasitology and Vector Biology Departments, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom

Background: The membrane protein Rft1 was proposed to flip Man₅GlcNAc₂-PP-dolichol (M5-DLO) to the ER lumen for N-glycoprotein biosynthesis.

Results: Rft1-null *Trypanosoma brucei* has a normal steady-state level of mature dolichol-linked oligosaccharide (mDLO) and significant N-glycosylation.

Conclusion: Rft1 is not required for M5-DLO flipping *in vivo* but aids conversion of M5-DLO to mDLO by another mechanism.

Significance: The M5-DLO flippase remains to be identified.

Mature dolichol-linked oligosaccharides (mDLOs) needed for eukaryotic protein N-glycosylation are synthesized by a multistep pathway in which the biosynthetic lipid intermediate Man₅GlcNAc₂-PP-dolichol (M5-DLO) flips from the cytoplasmic to the luminal face of the endoplasmic reticulum. The endoplasmic reticulum membrane protein Rft1 is intimately involved in mDLO biosynthesis. Yeast genetic analyses implicated Rft1 as the M5-DLO flippase, but because biochemical tests challenged this assignment, the function of Rft1 remains obscure. To understand the role of Rft1, we sought to analyze mDLO biosynthesis *in vivo* in the complete absence of the protein. Rft1 is essential for yeast viability, and no Rft1-null organisms are currently available. Here, we exploited *Trypanosoma brucei* (Tb), an early diverging eukaryote whose Rft1 homologue functions in yeast. We report that TbRft1-null procyclic trypanosomes grow nearly normally. They have normal steady-state levels of mDLO and significant N-glycosylation, indicating robust M5-DLO flippase activity. Remarkably, the mutant cells have 30–100-fold greater steady-state levels of M5-DLO than wild-type cells. All N-glycans in the TbRft1-null cells originate from mDLO indicating that the M5-DLO excess is not available for glycosylation. These results suggest that rather than facilitating M5-DLO flipping, Rft1 facilitates conversion of M5-DLO to mDLO by another mechanism, possibly by acting as an M5-DLO chaperone.

Protein N-glycosylation is ubiquitous in eukaryotes. N-Linked oligosaccharides direct folding, quality control, and degradation of most proteins that enter the secretory pathway and also influence their subsequent trafficking (1). The importance of N-linked oligosaccharides is evinced by the discovery of human congenital disorders of glycosylation (2), in which errors in oligosaccharide synthesis or assembly result in developmental, neurological, and metabolic dysfunction, often with life-threatening consequences. Consequently, detailed knowledge of the mechanisms of N-linked oligosaccharide assembly is critically important for understanding human physiology.

The N-linked oligosaccharide moiety is assembled on a dolichyl diphosphate lipid carrier before being transferred *en bloc* to glycosylation sequons (Asn-Xaa-(Ser/Thr)) in nascent proteins as they enter the lumen of the endoplasmic reticulum (ER)⁵ (3–5). Synthesis of the dolichol-linked oligosaccharide (DLO) is a multistep process that initially generates Man₅GlcNAc₂-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER (Fig. 1). M5-DLO is then flipped across the membrane to the ER lumen where it is elaborated in a series of reactions to mature DLO (mDLO). Metazoan mDLOs have a Glc₃Man₉GlcNAc₂ glycan, although mDLOs in other eukaryotes have smaller glycans. For example, mDLO in procyclic forms of the parasitic protozoan *Trypanosoma brucei* has a Man₉GlcNAc₂ glycan (6) that, after transfer to protein, is trimmed by mannosidases to generate “processed” N-glycans (Fig. 1).

The molecular machinery required for DLO assembly has been largely identified, except for the lipid flippases responsible for translocating M5-DLO and other dolichol-based lipids

* This work was supported, in whole or in part, by National Institutes of Health Grants AI35739 (to J. D. B.), GM38545 (to M. A. L.), and GM71041 (to A. K. M.). This work was also supported by Swiss National Science Foundation Grant 31003A-130815 (to P. B.) and Wellcome Trust Grant 093691MA (to A. A. S.).

✂ Author's Choice—Final version full access.

¹ These authors contributed equally to this work.

² To whom correspondence may be addressed. E-mail: Mark.Lehrman@UTSouthwestern.edu.

³ To whom correspondence may be addressed. E-mail: peter.buetikofer@ibmm.unibe.ch.

⁴ To whom correspondence may be addressed: Dept. of Biochemistry, Weill Cornell Medical College, 1300 York Ave., New York, NY 10065. Tel.: 212-746-5941; Fax: 212-746-8875; E-mail: akm2003@med.cornell.edu.

⁵ The abbreviations used are: ER, endoplasmic reticulum; M5-DLO, Man₅GlcNAc₂-PP-dolichol; mDLO, mature dolichol-linked oligosaccharide; PNGase F, N-glycosidase F; FACE, fluorophore-assisted carbohydrate electrophoresis; Endo H, endoglycosidase H; α 1,2m, α 1,2-mannosidase; ANDS, 7-amino-1,3-naphthalenedisulfonic acid; CPY, carboxypeptidase Y; ConA, concanavalin A.




FIGURE 1. DLO biosynthesis and protein N-glycosylation in *T. brucei* procyclic cells. Dolichyl phosphate (top left) is sequentially glycosylated by UDP-GlcNAc- and GDP-Man-utilizing glycosyltransferases to generate M5-DLO on the cytoplasmic side of the ER. M5-DLO is translocated across the ER membrane by the M5-DLO flippase. In the ER lumen, it is extended to mature M9-DLO by mannosyltransferases that use mannose phosphate dolichol (MPD) as the mannosyl donor. Mannose phosphate dolichol (bottom left) is synthesized on the cytoplasmic face of the ER and flipped in by a mannose phosphate dolichol flippase to participate in luminal mannosyl transfer reactions. In procyclic form trypanosomes, oligosaccharyltransferase (OST) transfers an M9 glycan from mDLO to Asn residues of Asn-Xaa-(Ser/Thr) glycosylation sequons within ER-translocated proteins. The dolichyl diphosphate generated as a result is converted to dolichyl phosphate that then flips back across the ER to reinitiate DLO biosynthesis. N-Glycans are trimmed by luminal mannosidases to generate processed structures such as the example on the right.

across the ER membrane (Fig. 1) (3, 5, 7). This impasse appeared to be broken when Ng *et al.* (8) and later Helenius *et al.* (9), working with the yeast *Saccharomyces cerevisiae*, concluded that the ER membrane protein Rft1 is required directly for membrane translocation of M5-DLO. These investigators showed that yeast cells in which Rft1 expression was reduced to levels much lower than normal (though not nil) accumulate M5-DLO and hypoglycosylate proteins as would be expected for cells deficient in M5-DLO flippase activity. They also showed that overexpression of Rft1 alleviated the poor growth of *alg11Δ* cells that synthesize Man₃GlcNAc₂-PP-dolichol (M3-DLO) rather than M5-DLO on the cytoplasmic face of the ER. Within the framework of their proposal that Rft1 is a DLO flippase, they suggested that overexpression of Rft1 increased the predicted low rate of M3-DLO flipping to a level that could sustain the growth of *alg11Δ* cells.

The assignment of Rft1 as the M5-DLO flippase was challenged by biochemical studies. Sealed microsomes prepared from Rft1-depleted and Rft1-replete yeast cells were indistinguishable in their ability to synthesize mDLO, indicating that although Rft1 may have a critical role in mDLO biosynthesis *in vivo*, it was dispensable *in vitro* (10). Further concerns with the proposed role of Rft1 as the M5-DLO flippase were revealed by biochemical reconstitution experiments. M5-DLO flipping was demonstrated in proteoliposomes reconstituted with rat liver or yeast ER membrane proteins (11–13). Flipping in this reconstituted system was highly specific (13); a nonbiological structural isomer of M5-DLO was not flipped, and M6-DLO and larger DLO structures were flipped slowly, consistent with the

early work of Snider and Rogers (14). Importantly, proteoliposomes lacking Rft1 were identical in their activity to Rft1-containing preparations, and biochemical fractionation of ER membrane protein extracts prior to reconstitution revealed that M5-DLO flippase activity could be resolved from Rft1 by a variety of methods, including velocity sedimentation and ion exchange chromatography (11, 12).

The cumulative data indicate that Rft1 is intimately involved in mDLO biosynthesis; however, its specific role in the pathway and its possible contribution to M5-DLO flipping remain enigmatic. To address this issue, we sought to analyze mDLO biosynthesis *in vivo* in the complete absence of the protein. As this could not be done in yeast where Rft1 is essential for viability under standard growth conditions, we turned to *T. brucei*, an early diverging eukaryote with an N-glycosylation pathway similar to that found in higher eukaryotes (15). *T. brucei* is a parasitic protozoan that causes sleeping sickness in humans and nagana in animals throughout sub-Saharan Africa. Compared with *S. cerevisiae* cells that grow rapidly and thus need N-glycosylation for osmoprotective cell wall assembly, we reasoned that the relatively slow-growing trypanosomes might be able to tolerate the absence of Rft1, especially if the protein provided an accessory rather than a core function in DLO biosynthesis. We identified the *T. brucei* Rft1 homologue and demonstrated that it provides the essential function of Rft1 in yeast. We now report that the procyclic form of *T. brucei* tolerates homozygous null disruptions of the *TbRft1* gene. Remarkably, the *TbRft1*-null strains synthesize normal levels of mDLO and transfer mDLO-derived glycans to protein but nevertheless accumulate M5-DLO and underglycosylate proteins. Our results show that M5-DLO flipping occurs in the complete absence of Rft1 *in vivo* but that Rft1 nonetheless influences the conversion of M5-DLO to M9-DLO.

EXPERIMENTAL PROCEDURES

Materials—Unless otherwise stated, all reagents were of analytical grade and purchased from Sigma or Merck. Restriction enzymes were from Fermentas (St. Leon-Rot, Germany) and antibiotics from Sigma, Invivogen (Nunningen, Switzerland), or Invitrogen. EasyTag[®] Expre^{35S} protein labeling mix was from PerkinElmer Life Sciences. BioMax MS and MXB films were from GE Healthcare.

Trypanosome Cultures—*T. brucei* strain Lister 427 procyclic forms were cultured at 27 °C in SDM-79 containing 5% heat-inactivated fetal bovine serum. Rft1 knock-out clones were grown under the same condition, in the presence of 15 μg/ml G418 for the single allele knock-out and an additional 10 μg/ml blasticidin for the double allele knock-out clones.

Generation of *TbRft1*-null Cells—Constructs to replace the endogenous *TbRft1* genes were based on the pKO plasmid containing resistance cassettes consisting of the following elements (5' to 3'): the *EPI-EP2* procyclin intergenic region, a G418 or blasticidin resistance gene, and the tubulin βα intergenic region (16). A 397-bp 5' and a 427-bp 3' recombination sequence flanked the resistance cassettes. Recombination sequences adjacent to the *TbRft1* open reading frame were obtained by PCR amplification using primers 5'_forward gccaagcttacatgtcgtttaagttccgc and 5'_reverse gcaatccacac-

caaaagtacagctgctgc for the 5'-recombination sequence and 3'-forward cgctctagatggtgaaggcgctggttc and 3'-reverse gcg-gagctcagcttgagtcctatgagtg for the 3'-recombination sequence (HindIII, EcoRI, XbaI, and SacI restriction sites are underlined). Prior to transfection into *T. brucei* 427 procyclic forms, plasmids were digested upstream and downstream of the recombination sequences using HindIII and SacI. Clones were obtained by limiting dilution under antibiotic selection using 15 μ g/ml G418 and/or 10 μ g/ml blasticidin. Clones were PCR-tested for correct integration using primer 5' UTR_control ggaagcgcaat-cattcagag, which binds 50 bp upstream of the 5' recombination sequence, in combination with different reverse primers.

To introduce an ectopic copy of *Rft1* into *TbRft1*-null cells, *TbRft1* was amplified with primers *TbRft1*_forward gcccaagct-tatggacttcaaagcacagctg and *TbRft1*_reverse gccctcagactactcgc-cgcttctttttg and cloned into a pLEW100-based expression vector (17) (HindIII and XhoI restriction sites are underlined). Clones were obtained by limiting dilution under antibiotic selection using 2 μ g/ml puromycin.

Southern Blot Analysis—For Southern blot analysis, 1.2 μ g of AgeI or SacII/SmaI-digested genomic DNA from wild-type and mutant cells was separated on a 1% agarose gel and transferred to Hybond-N+ nylon transfer membrane (GE Healthcare) using 10 \times SSC buffer (150 mM Na₃-citrate, pH 7.0, containing 1.5 M NaCl). The membrane was probed with a 427-bp ³²P-labeled PCR product of the *TbRft1* 3' recombination sequence generated with the prime-a-gene labeling system (Promega, Dübendorf, Switzerland). The hybridized probe was detected by autoradiography using BioMax MS films in combination with intensifying screens.

³⁵S Labeling of Trypanosomes and Immunoprecipitation of p67—Wild-type and *TbRft1*-null cells were labeled with EasyTag[®] Expre³⁵S essentially as described before (18, 19). Briefly, trypanosomes were washed twice in PBS and resuspended at 10⁷/ml in pre-warmed (27 °C) Met/Cys-deficient SDM-79 containing 5% dialyzed FBS for 10 min. Labeling was initiated by the addition of [³⁵S]Met/Cys to 100 μ Ci/ml. After 60 min of incubation, cells were washed with cold buffer and resuspended in cold solubilization buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, containing 1% Nonidet-40, 0.1% SDS, and 0.5% deoxycholate). After centrifugation for 5 min at 1500 \times g in a microcentrifuge, mouse anti-p67 was added to the clear supernatant and incubated under constant rotation for 60 min at 4 °C. Antibody-bound p67 was precipitated using protein A-agarose for 60 min at 4 °C under rotation, washed, and resuspended in electrophoresis buffer.

Enzyme Treatments—Parasite lysates or immunoprecipitated proteins were treated with N-glycosidase F (PNGase) or endoglycosidase H (Endo H) according to the manufacturer's instructions.

SDS-PAGE, Autoradiography/Fluorography—Parasite lysates or immunoprecipitated proteins were separated on 10% polyacrylamide gels under reducing conditions (20). ³⁵S-Labeled proteins were detected after fixation of the gel and exposure to BioMax MS films at -70 °C.

Fluorophore-assisted Carbohydrate Electrophoresis (FACE) Analysis of Trypanosomal Glycoconjugates—Trypanosomes were collected by centrifugation and washed twice with ice-

cold PBS. Methanol (room temperature) was added to the tube, and the contents were disrupted by vigorously vortexing. The suspensions were dried and processed for FACE analyses as described (21, 22). In brief, after most lipids were removed by extraction with chloroform/methanol (2:1, by volume) and aqueous components removed by extraction with water, DLOs were obtained by extraction with chloroform/methanol/water (10:10:3, by volume). N-Linked glycoproteins remained in the residual material. The glycan units of DLOs were released with weak acid. N-Glycans were released with PNGase F and further purified by ion exchange. All glycans were conjugated with 7-amino-1,3-naphthalenedisulfonic acid (ANDS) and resolved on an oligosaccharide profiling gel, with all loads normalized to total protein in the chloroform/methanol/water (10:10:3) residue. When necessary, the fluorescently conjugated glycans were incubated in 50 mM sodium citrate buffer, pH 5.5, for 18 h at 37 °C with 100 units of Endo H (New England Biolabs) and/or 0.05 milliunits of α -1,2-mannose-specific mannosidase (*Aspergillus saitoi*, Prozyme). Fluorescently labeled oligosaccharides were detected with a Bio-Rad Fluor-S scanner and quantified with Quantity-One software.

Flow Cytometry Analysis—Trypanosomes at mid-log phase (10⁷ parasites) were harvested by centrifugation at 1500 \times g for 10 min at 4 °C and resuspended in 200 μ l of cold SDM-79. Concanavalin A-FITC conjugate was added to a final concentration of 3 μ g/ml. After 1 h of incubation in the dark on ice, 1 ml of cold SDM-79 was added, and parasites were centrifuged as above. After washing once in cold SDM-79, trypanosomes were resuspended in 2 ml of cold SDM-79 and analyzed by flow cytometry (BD FACSCalibur or FACScan) at a concentration of 5 \times 10⁵ cells/ml. Data were analyzed using flow cytometry analysis software FlowJo.

Immunofluorescence Microscopy—Parasites were processed for immunofluorescence microscopy exactly as described before (23), using antibodies against p67 (19) and *TbCatL* (24) at dilutions of 1:1000 and 1:500, respectively. Secondary antibodies Alexa Fluor 594 goat α -mouse IgG (Invitrogen) and Alexa Fluor 488 goat α -rabbit IgG (Invitrogen) were used at dilutions of 1:1000.

RESULTS

T. brucei Rft1 Is Functionally Equivalent to S. cerevisiae Rft1—We identified an *Rft1* orthologue in *T. brucei* by BLAST searching the predicted proteome of *T. brucei* strain TREU 927 using human and *S. cerevisiae* *Rft1* sequences as queries. We retrieved a single orthologous sequence, Tb11.01.3540, that was annotated as a 598-amino acid hypothetical protein. Topology prediction programs indicated that Tb11.01.3540 is a membrane protein with multiple transmembrane spans. To determine whether Tb11.01.3540 could functionally substitute for yeast *Rft1* (*ScRft1*), we used a haploid yeast strain (YG1137) (9) in which *ScRft1* is expressed under the control of the glucose-repressible *GAL1-10* promoter. On shifting YG1137 cells from galactose- to glucose-containing medium, *ScRft1* expression is repressed and the cells fail to grow (Fig. 2A). At the same time, carboxypeptidase Y (CPY), a vacuolar protease with four N-glycans, becomes hypoglycosylated, with ever fewer glycosylation sites on the protein being occupied as the incubation time in




FIGURE 2. *TbRft1* is functionally equivalent to *S. cerevisiae* Rft1. A, YG1137 yeast cells (in which Rft1 expression is controlled by the glucose-repressible *GAL1–10* promoter) were transfected with an episomal *URA3* plasmid encoding *TbRft1* (+) or an empty vector (–). Serial dilutions were spotted on minimal uracil-free solid media containing either 2% glucose (Glc) or galactose (Gal), and incubated for 2 days at 30 °C. B, YG1137 cells were transfected as in A and grown on Glc- or Gal-containing minimal media at 30 °C. Extracts were prepared at the indicated times and analyzed by SDS-PAGE and immunoblotting with anti-carboxypeptidase Y (CPY) antibodies. Mature and hypoglycosylated forms of CPY, particularly evident in the 20 h sample from Glc-grown cells transfected with the empty vector, are indicated by dots.

glucose-containing media is increased and ScRft1 levels decrease (Fig. 2B, lanes indicated *TbRft1*–) (9–11). Heterologous expression of Tb11.01.3540 enabled YG1137 cells to grow on glucose-containing media (Fig. 2A) and prevented CPY hypoglycosylation (Fig. 2B, lanes indicated *TbRft1*+) indicating that the trypanosome protein, henceforth *TbRft1*, is functionally equivalent to ScRft1.

***TbRft1* Is Nonessential in Procyclic Form Trypanosomes**—We used homologous recombination to replace the *TbRft1* alleles in diploid procyclic cells with G418 and blasticidin resistance genes, eliminating the ability to express any form of *TbRft1* protein. We recovered viable clones of *TbRft1*-null trypanosomes that grew nearly normally (Fig. 3A). The generation time of two independent *TbRft1*-null clones was 15.3 ± 0.9 and 14.4 ± 0.2 h, compared with 11 ± 0.2 and 13.1 ± 0.5 h for wild-type cells and single knock-out cells, respectively. These data suggest that growth rate is sensitive to *TbRft1* gene dosage (in contrast to effects on glycosylation, see below). Southern blot analyses (Fig. 3B) confirmed that we had indeed disrupted both alleles of *TbRft1* and that the growth of the cells was not due to inappropriate integration of the drug resistance genes elsewhere in the genome rather than at the *TbRft1* locus. We conclude that *TbRft1* is a nonessential protein in *T. brucei* procyclic forms in culture.

To determine whether the *TbRft1*-null trypanosomes had a glycosylation defect, we incubated the cells with FITC-ConA, a fluorescent conjugate of the mannose-binding lectin concanavalin A, and quantified cell surface fluorescence by flow cytometry. *TbRft1*-null trypanosomes bound ~75% less FITC-ConA than wild-type cells (Fig. 3C). This was specifically due to the lack of Rft1, as FITC-ConA binding could be restored by ectopic expression of *TbRft1* (Fig. 3D, histogram labeled *rescue*). Thus, despite their robust growth characteristics, the *Rft1*-null cells show decreased levels of cell surface glycosylation.

Dolichol-linked Oligosaccharide Synthesis and Protein N-Glycosylation in *TbRft1*-null Cells—To examine the glycosylation phenotype of the *Rft1*-null trypanosomes in more detail, we used FACE (21), a sensitive method to quantify steady-state levels of oligosaccharides. The cells were treated with organic solvent to extract DLOs and precipitate proteins.




FIGURE 3. Characterization of *TbRft1*-null trypanosomes. A, cumulative growth of wild-type and mutant *T. brucei* procyclic forms. B, Southern blot analysis. *Agel* or *SacII*/*SmaI*-digested genomic DNA from wild type and mutant trypanosomes was separated on an agarose gel, transferred to hybond-N+ nylon transfer membrane, and probed with a 427-bp 32 P-labeled PCR product of the *TbRft1* 3' recombination sequence. The hybridized probe was detected by autoradiography. C, ConA reactivity. Wild-type (wt) and *TbRft1*-null (–/–) trypanosomes were fixed and incubated with or without FITC-ConA. The extent of labeling was determined by flow cytometry. The corresponding profiles of unlabeled cells are shown as line traces, without fill. D, flow cytometry analysis of *TbRft1*-null cells expressing *TbRft1* (*rescue*) compared with *TbRft1*-null and wild-type trypanosomes. Analysis was done as in C.

Oligosaccharides were released from DLOs and N-glycoproteins with mild acid and peptide:N-glycosidase F (PNGase F) treatment, respectively. N-Glycans were further purified by ion exchange chromatography to enrich neutral glycans, including high mannose structures. All glycans were conjugated with ANDS fluorophore and analyzed on an oligosaccharide profiling gel.

The profile of DLOs (Fig. 4A) in *TbRft1*-null trypanosomes was striking. The steady-state level of M9-DLO in the *TbRft1*-null cells (24.2 ± 2.2 pmol/mg) was similar to that in wild-type cells (22.8 ± 0.2 pmol/mg) indicating that the null cells have an intact DLO assembly pathway. However, the steady-state level of M5-DLO in the *TbRft1*-null trypanosomes was >40-fold higher than that in wild-type cells (382.7 ± 34 versus 8.7 ± 0.9 pmol/mg). Also apparent was the accumulation of M6-DLO, M7-DLO, and M8-DLO (Fig. 4A), whose consumption has no obvious requirement for the M5-DLO flippase. Cumulative results obtained from independent experiments and individual *TbRft1*-null clones (Table 1) indicate that this pattern is highly reproducible; *TbRft1*-null cells have a 30–100-fold higher steady-state level of M5-DLO compared with wild-type cells but an essentially normal level of M9-DLO (Table 1). Although a reduction in *TbRft1* gene dosage had a mild effect on the rate of growth (Fig. 3A), steady-state levels of the various glycoconjugates were similar in wild-type and heterozygous trypanosomes (Table 1).




FIGURE 4. M9-DLO is synthesized and used for N-glycosylation in TbRft1-null cells while biosynthetic M5-DLO accumulates. DLOs and total neutral N-glycans from wild-type (wt), TbRft1-heterozygous (+/-), and TbRft1-null (-/-) trypanosomes were analyzed by FACE. The positions of glucose oligomers (G4 to G7) and dolichol-linked glycan standards (M3-G3M9) are shown. **A**, DLOs from duplicate samples of wild-type (lanes 2 and 3), TbRft1-null (lanes 4 and 5), and TbRft1-heterozygous (lanes 6 and 7) cells. Glycans were released from the DLO fraction and labeled with ANDS prior to analysis. **B**, DLOs from rodent liver (control), or wild type (wt), or TbRft1-null trypanosomes. ANDS-labeled glycans were incubated in the absence or presence of Endo H or α 1,2m as indicated. Cleavage by Endo H releases GlcNAc-ANDS, with loss of fluorescent label from the parent glycan. **C**, total neutral N-glycans, as for **A**. **D**, analysis of total neutral N-glycans by glycosidase digestion, as for **B**, except that the control used was a DLO preparation from rodent kidney, which has a relatively high proportion of nonglycosylated DLOs. **E**, schematic showing the glycosidase digestion pattern obtained for various glycans. bM5, biosynthetic biantennary $\text{Man}_5\text{GlcNAc}_2$; pM5, processed triantennary $\text{Man}_5\text{GlcNAc}_2$ (see also Fig. 1).

We considered whether the accumulated M5-DLO is a direct product of the DLO biosynthetic pathway ("biosynthetic M5" (Fig. 4E)) or whether it is derived from mature M9-DLO as a result of the action of cellular mannosidases ("processed M5" (Fig. 4E)). To distinguish these possibilities, we determined the susceptibility of the accumulated M5-DLO to Endo H and α 1,2-mannosidase (α 1,2m). As outlined schematically in Fig. 4E, biosynthetic M5 is susceptible to α 1,2m yielding $\text{Man}_3\text{GlcNAc}_2$ -ANDS but resistant to Endo H; in contrast, processed M5 is susceptible to Endo H (the GlcNAc-ANDS product is not retained within the resolving gel) but resistant to α 1,2m. The glycosidase digests shown in Fig. 4B indicate clearly that the accumulated M5-DLO is "biosynthetic," i.e. it corresponds to a DLO biosynthesis intermediate.

We next analyzed neutral N-glycans released by PNGase F. *T. brucei* procyclic forms almost exclusively make high mannose type N-glycans (25). The profile of N-glycans seen in TbRft1-null trypanosomes was identical to that in wild-type cells except that the total level of N-glycans was, on average, ~67% lower (Fig. 4C and Table 1), consistent with the ~75% lower surface reactivity of TbRft1-null cells toward ConA (Fig. 3C). The full range of N-glycans was observed in TbRft1-null cells, from $\text{Man}_5\text{GlcNAc}_2$ to $\text{Man}_9\text{GlcNAc}_2$. Glycosidase digests (Fig. 4D, illustrated schematically in Fig. 4E) indicated that the $\text{Man}_5\text{GlcNAc}_2$ species recovered in the N-glycan fraction corresponds to processed M5 (Fig. 4E). This result indicates that in Rft1-null cells a higher order oligosaccharide such as M9 is transferred to proteins and subsequently trimmed by cellular mannosidases to processed M5. The cumulative data reveal that TbRft1-null trypanosomes have a complete N-glycosylation pathway but nevertheless accumulate large amounts of the M5-DLO biosynthetic intermediate that is not directly transferable to protein.

N-Glycosylation of p67 in TbRft1-null Cells—To refine our analyses of N-glycosylation in the TbRft1-null trypanosomes, we focused on a specific protein and chose p67, a well characterized lysosomal N-glycoprotein with 14 N-glycosylation sites (19). We immunoprecipitated p67 from trypanosomes that had been metabolically labeled with [^{35}S]methionine/cysteine and analyzed the protein by SDS-PAGE and fluorography. Fig. 5A shows the expected ~100-kDa band for fully glycosylated p67 in wild-type cells and a lower molecular weight (~72 kDa) diffuse band in TbRft1-null cells (Fig. 5A, compare lane 2 with lane 1). Treatment with either Endo H or PNGase F converted the diffuse band to an ~67-kDa product (Fig. 5A). Thus, p67 in

TABLE 1

Steady-state levels of M9-DLO, M5-DLO, total DLOs and total neutral N-glycans in wild-type, TbRft1-null, and single knock-out trypanosomes

Mean \pm range of duplicate measurements is quoted as picomoles of glycoconjugate per mg of protein; ND means not determined. Two different TbRft1-null clones (A3 and B1(2)) were analyzed, alongside single knock-out (3F) and wild-type (427) cells. Raw data for experiment 1 are depicted in Fig. 3, A and C.

Experiment	Glycoconjugate	427 (+/+)	A3 (-/-)	B1(2) (-/-)	3F (+/-)
1	M9-DLO	22.8 \pm 0.2	24.2 \pm 2.2	ND	24.2 \pm 1.6
	M5-DLO	8.7 \pm 0.9	382.7 \pm 34	ND	12.3 \pm 0.5
	Σ DLO	32.2 \pm 1.4	423.7 \pm 36	ND	40.4 \pm 2.2
	Σ N-glycans	687 \pm 16	294 \pm 36	ND	727 \pm 2
2	M9-DLO	17.4 \pm 0.6	6.4 \pm 0.8	14.2 \pm 1.8	25.2 \pm 0.4
	M5-DLO	8.4 \pm 0.4	248.2 \pm 2.2	840.8 \pm 0.4	28.6 \pm 3.2
	Σ DLO	25.8 \pm 1	254.6 \pm 3	855 \pm 2.2	54 \pm 2.8
	Σ N-glycans	857 \pm 100	323 \pm 27	454 \pm 16	907 \pm 82




FIGURE 5. Analysis of p67. A, analysis of p67 from wild-type and TbRft1-null cells. Trypanosomes were metabolically labeled with ^{35}S -labeled amino acids and lysed, and p67 was immunoprecipitated and analyzed by SDS-PAGE and fluorography, either directly or after Endo H or PNGase F treatment. B, fluorescence micrographs obtained using DAPI, as well as antibodies against p67 and TbCatL. DAPI staining reveals kinetoplast and nuclear DNA. DIC, differential interference contrast.

TbRft1-null cells is N-glycosylated, and the glycans are fully Endo H-sensitive indicating that they have the expected oligomannose structure.

We observed that Endo H-treated p67 from TbRft1-null trypanosomes migrates slightly faster than the corresponding sample from wild-type cells (Fig. 5A, compare lane 4 with lane 3). This is likely because fewer N-glycosylation sites are occupied in p67 from TbRft1-null cells, and therefore, there are fewer GlcNAc residues left on the protein after Endo H cleavage. Differences in migration are also observed in PNGase F-treated p67 samples (Fig. 5A, compare lane 6 with lane 5). In this case, lower site occupancy would result in fewer Asn residues being converted into negatively charged Asp residues after PNGase F digestion of p67 from TbRft1-null trypanosomes, making this protein migrate slightly faster than its counterpart from wild-type cells. We conclude that fewer N-glycosylation sites are occupied in p67 from TbRft1-null cells compared with wild-type cells, thus explaining its faster and more diffuse migration on SDS-PAGE. Based on gel mobility, we estimate that p67 in the TbRft1-null trypanosomes has 2–4 N-glycans.

Despite being underglycosylated, p67 is correctly localized to the lysosome in TbRft1-null cells. Immunofluorescence microscopy (Fig. 5B) revealed a single organelle in the region between the nucleus and the posterior flagellar pocket that was stained with anti-p67 antibodies as well as with antibodies against TbCatL, a trypanosomal cathepsin L orthologue (24).


DISCUSSION

We generated an Rft1-null cell, making it possible for the first time to characterize quantitatively the consequences of complete Rft1 absence by measuring the steady-state levels of key DLO intermediates and N-glycoproteins. In contrast, previous

analyses of Rft1 function *in vivo* were done on cells in which the protein was acutely depleted but not eliminated (9). Our results clearly show that TbRft1-null procyclic trypanosomes can execute the entire ER N-glycosylation pathway, *i.e.* synthesis of M9-DLO, transfer of $\text{Man}_5\text{GlcNAc}_2$ to proteins, and trimming of N-glycans. However, measurements of the steady-state levels of DLO intermediates by FACE show that although M9-DLO levels are unaffected, the mutant cells accumulate large amounts of the M5-DLO biosynthetic intermediate. Accumulation of the downstream intermediates M6-DLO, M7-DLO, and M8-DLO was also detected. These data indicate that TbRft1 impacts the multistep conversion of M5-DLO to M9-DLO.

Our results are inherently inconsistent with the assignment of Rft1 (8, 9) as the M5-DLO flippase. Another protein, yet to be identified, very likely plays this role because spontaneous flip-flop of M5-DLO (26) is too slow to supply the DLO biosynthetic pathway in TbRft1-null trypanosomes; the $t_{1/2}$ for M5-DLO flipping in synthetic bilayers is predicted to be $\gg 100$ h, *i.e.* much slower than that for common phospholipids (27). It is formally possible that M5-DLO flipping in the mutant cells is the result of a nonspecific process, involving membrane factors that do not normally serve this function. However, given our earlier demonstration of a chromatographically discrete protein fraction with structure-specific M5-DLO flipping activity *in vitro* (11–13), there is little justification for invoking such a model.

For insights into the observed steady-state levels of M5-DLO and M9-DLO in wild-type and TbRft1-null cells, we modeled the DLO pathway as a sequential, irreversible series of reactions in which a source (S) is converted to M5-DLO, then to M9-DLO, and finally to product(s) (P). This simplification is possible because in steady state, a series of reactions can be replaced by a single reaction without invoking a rate-limiting step. Thus, in Reaction 1,



where the rate constant k_1 describes the set of reactions leading to the production of M5-DLO, the rate constant k_2 characterizes the multistep conversion of M5-DLO to M9-DLO, and the rate constant k_3 indicates the conversion of M9-DLO to products. The steady-state levels of M5-DLO and M9-DLO are shown in Equation 1,

$$\text{M5-DLO}_{ss} = (k_1/k_2)S$$

$$\text{M9-DLO}_{ss} = (k_2/k_3)\text{M5-DLO}_{ss} = (k_1/k_3)S \quad (\text{Eq. 1})$$

Thus, the simplest explanation for the ~ 100 -fold higher level of M5-DLO_{ss} in TbRft1-null cells is that k_2 is ~ 100 -fold lower in these cells compared with wild-type cells. This change does not affect M9-DLO_{ss} , which does not depend on k_2 .

How does TbRft1 affect k_2 , *i.e.* conversion of M5-DLO to M9-DLO? The processes encapsulated in k_2 are minimally the M5-DLO flipping event and the four luminal mannosyl transfer reactions. As the cumulative biochemical data reported earlier

(10–12) and the *in vivo* results presented here demonstrate that M5-DLO flipping does not require Rft1, and the luminal mannosyltransferases are known (Alg3, Alg9, and Alg12, with Alg9 carrying out two of the four mannosylations (7)), we conclude that Rft1 carries out its role separately from the core machinery required for conversion of M5-DLO to M9-DLO. We suggest that Rft1 plays an accessory albeit important role in M9-DLO biosynthesis. For example, it may control k_2 by functioning as a DLO chaperone to supply M5-DLO to the flippase or mannosyltransferases or to increase the chemical activity of M5-DLO by preventing its possible aggregation. Similar considerations apply to M6-, M7-, and M8-DLO as these lipids also accumulate in the TbRft1-null cells. Alternatively, it could stabilize a complex of the luminal mannosyltransferases, thus enabling substrate channeling. Complex formation involving components of the DLO biosynthetic machinery has been previously reported (28, 29). In this context, it is interesting to note that disease-causing mutations in human Rft1 are located in hydrophilic loop regions of the protein that are predicted to be in the ER lumen (30); these functionally important loops could conceivably be involved in Rft1's proposed role as luminal M5-DLO chaperone or its proposed role as a partner of luminal mannosyltransferases. As discussed previously (11, 12), Rft1's function may resemble that of Lec35/MPDU1, a metazoan protein that is involved in luminal mannosyl transfer reactions *in vivo* (31). Lec35/MPDU1 was originally thought to be an excellent candidate for the mannose-phosphate dolichol flippase (Fig. 1), but the current consensus is that it acts as a dolichyl-lipid chaperone (31, 32).

Why is N-glycosylation reduced even though M9-DLO_{ss} levels are normal in TbRft1-null cells? Steady-state measurements do not give information about flux. Thus, although M9-DLO_{ss} levels are normal, the rates of M9-DLO synthesis and consumption may be coordinately reduced by factors (yet to be determined) secondary to the absence of TbRft1. M9-DLO is subject to at least two known fates (collectively described by the rate constant k_3 in Reaction 1), consumption by oligosaccharyltransferase for protein N-glycosylation and turnover, possibly by regulated cleavage of its pyrophosphate linkage (22). The balance between the two fates can be altered without affecting k_3 or M9-DLO_{ss}. Thus, with less M9-DLO being consumed for N-glycosylation, greater turnover could be accommodated in the TbRft1-null strain. However, it is unlikely that mannose 6-phosphate-dependent hydrolysis of DLOs described by Gao *et al.* (22, 33) could contribute to DLO turnover because M9-DLO appears not to be a substrate for this process. Alternatively, M9-DLO levels could be limiting in both wild-type and TbRft1-null trypanosomes. In this event, the reduced rate of production of M9-DLO in the TbRft1-null cells could account for the observation of fewer glycans per protein.

Where does M5-DLO accumulate in TbRft1-null cells? Wild-type procyclic trypanosomes normally transfer M9 oligosaccharides to proteins and process these to triantennary M5 structures (Fig. 1). When biosynthetic M5-DLO is the only donor available to oligosaccharyltransferase in procyclic forms of *T. brucei*, proteins are underglycosylated and N-glycans are aberrantly processed to biantennary complex structures (34). The M5-DLO that accumulates in TbRft1-null cells could

potentially compete with mature M9-DLO in the oligosaccharyltransferase reaction, resulting in biantennary complex N-glycans that would be resistant to Endo H digestion. This is not the case; analysis of total N-glycans (Fig. 4D), as well as N-glycans on p67 (Fig. 5A), indicates structures that are completely susceptible to Endo H. The M5 structures that we detected in N-glycans were also Endo H-sensitive; they were derived by normal processing of mature M9 N-glycans and did not originate by direct transfer of biosynthetic M5. Thus, M5-DLO does not compete with M9-DLO and therefore must not have access to the site of oligosaccharyl transfer.

Either of two contrasting models could account for the segregation of accumulated M5-DLO from the site of oligosaccharyl transfer in the ER: model 1, M5-DLO accumulates on the cytoplasmic side of the ER, and model 2, M5-DLO accumulates on the luminal side of the ER, perhaps in an aggregated form with low chemical activity or in a region of the ER that is laterally segregated from the oligosaccharyltransferase. Examples of lateral segregation of reactions within a single pathway in the ER have been previously noted (35, 36). The models have implications for possible functions of Rft1. In model 1, Rft1 would function as an accessory protein to supply M5-DLO to the flippase on the cytoplasmic side of the ER, and in model 2, Rft1's function would be on the luminal side of the ER, possibly to prevent M5-DLO aggregation and increase its chemical activity, or chaperone M5-DLO between ER domains.

The two models predict different transbilayer orientations for M5-DLO; in model 1, M5-DLO would be mainly oriented toward the cytoplasm, and in model 2, M5-DLO would be able to flip bidirectionally between leaflets. Current biochemical approaches, *e.g.* capturing M5-DLO on the cytoplasmic side of intact ER preparations with a lectin (11, 14), would not be able to distinguish between these models as M5-DLO would be quantitatively captured in both cases. Indeed, unless it is known that the transbilayer distribution of M5-DLO is stable during the analysis, it would be difficult to make any conclusions about its orientation. Development of suitable techniques to distinguish between these models remains an objective for future work.

Acknowledgments—We acknowledge Christian Frank and Markus Aebi for yeast strain YG1137, Jeremy Dittman for discussions, and Francis Urquhart, Frank E. Wright, and Fishers Island oysters for stimulation.

REFERENCES

1. Hebert, D. N., Garman, S. C., and Molinari, M. (2005) The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. *Trends Cell Biol.* **15**, 364–370
2. Hennot, T. (2012) Diseases of glycosylation beyond classical congenital disorders of glycosylation. *Biochim. Biophys. Acta* **1820**, 1306–1317
3. Schenk, B., Fernandez, F., and Waechter, C. J. (2001) The in(side) and out(side) of dolichyl phosphate biosynthesis and recycling in the endoplasmic reticulum. *Glycobiology* **11**, 61R–70R
4. Burda, P., and Aebi, M. (1999) The dolichol pathway of N-linked glycosylation. *Biochim. Biophys. Acta* **1426**, 239–257
5. Sanyal, S., and Menon, A. K. (2009) Flipping lipids: why an' what's the reason for? *ACS Chem. Biol.* **4**, 895–909
6. Acosta-Serrano, A., O'Rear, J., Quellhorst, G., Lee, S. H., Hwa, K. Y., Krag,

- S. S., and Englund, P. T. (2004) Defects in the N-linked oligosaccharide biosynthetic pathway in a *Trypanosoma brucei* glycosylation mutant. *Eukaryot. Cell* **3**, 255–263
7. Larkin, A., and Imperiali, B. (2011) The expanding horizons of asparagine-linked glycosylation. *Biochemistry* **50**, 4411–4426
8. Ng, D. T., Spear, E. D., and Walter, P. (2000) The unfolded protein response regulates multiple aspects of secretory and membrane protein biogenesis and endoplasmic reticulum quality control. *J. Cell Biol.* **150**, 77–88
9. Helenius, J., Ng, D. T., Marolda, C. L., Walter, P., Valvano, M. A., and Aebi, M. (2002) Translocation of lipid-linked oligosaccharides across the ER membrane requires Rft1 protein. *Nature* **415**, 447–450
10. Rush, J. S., Gao, N., Lehrman, M. A., Matveev, S., and Waechter, C. J. (2009) Suppression of Rft1 expression does not impair the transbilayer movement of Man5GlcNAc2-P-P-dolichol in sealed microsomes from yeast. *J. Biol. Chem.* **284**, 19835–19842
11. Frank, C. G., Sanyal, S., Rush, J. S., Waechter, C. J., and Menon, A. K. (2008) Does Rft1 flip an N-glycan lipid precursor? *Nature* **454**, E3–4
12. Sanyal, S., Frank, C. G., and Menon, A. K. (2008) Distinct flippases translocate glycerophospholipids and oligosaccharide diphosphate dolichols across the endoplasmic reticulum. *Biochemistry* **47**, 7937–7946
13. Sanyal, S., and Menon, A. K. (2009) Specific transbilayer translocation of dolichol-linked oligosaccharides by an endoplasmic reticulum flippase. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 767–772
14. Snider, M. D., and Rogers, O. C. (1984) Transmembrane movement of oligosaccharide-lipids during glycoprotein synthesis. *Cell* **36**, 753–761
15. Parodi, A. J. (1993) N-Glycosylation in trypanosomatid protozoa. *Glycobiology* **3**, 193–199
16. Lamb, J. R., Fu, V., Wirtz, E., and Bangs, J. D. (2001) Functional analysis of the trypanosomal AAA protein TbVCP with trans-dominant ATP hydrolysis mutants. *J. Biol. Chem.* **276**, 21512–21520
17. Wirtz, E., Leal, S., Ochatt, C., and Cross, G. A. (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in *Trypanosoma brucei*. *Mol. Biochem. Parasitol.* **99**, 89–101
18. Bangs, J. D., Brouch, E. M., Ransom, D. M., and Roggy, J. L. (1996) A soluble secretory reporter system in *Trypanosoma brucei*. Studies on endoplasmic reticulum targeting. *J. Biol. Chem.* **271**, 18387–18393
19. Alexander, D. L., Schwartz, K. J., Balber, A. E., and Bangs, J. D. (2002) Developmentally regulated trafficking of the lysosomal membrane protein p67 in *Trypanosoma brucei*. *J. Cell Sci.* **115**, 3253–3263
20. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685
21. Gao, N., and Lehrman, M. A. (2006) Nonradioactive analysis of lipid-linked oligosaccharide compositions by fluorophore-assisted carbohydrate electrophoresis. *Methods Enzymol.* **415**, 3–20
22. Gao, N., Shang, J., Huynh, D., Manthathi, V. L., Arias, C., Harding, H. P., Kaufman, R. J., Mohr, I., Ron, D., Falck, J. R., and Lehrman, M. A. (2011) Mannose 6-phosphate regulates destruction of lipid-linked oligosaccharides. *Mol. Biol. Cell* **22**, 2994–3009
23. Serricchio, M., and Bütikofer, P. (2012) An essential bacterial-type cardiolipin synthase mediates cardiolipin formation in a eukaryote. *Proc. Natl. Acad. Sci. U.S.A.* **109**, E954–961
24. Peck, R. F., Shiflett, A. M., Schwartz, K. J., McCann, A., Hajduk, S. L., and Bangs, J. D. (2008) The LAMP-like protein p67 plays an essential role in the lysosome of African trypanosomes. *Mol. Microbiol.* **68**, 933–946
25. Hwa, K. Y., and Khoo, K. H. (2000) Structural analysis of the asparagine-linked glycans from the procyclic *Trypanosoma brucei* and its glycosylation mutants resistant to concanavalin A killing. *Mol. Biochem. Parasitol.* **111**, 173–184
26. Lennarz, W. J. (1987) Protein glycosylation in the endoplasmic reticulum: current topological issues. *Biochemistry* **26**, 7205–7210
27. Chalal, M., Menon, I., Turan, Z., and Menon, A. K. (2012) Reconstitution of glucosylceramide flip-flop across the endoplasmic reticulum: implications for the mechanism of glycosphingolipid biosynthesis. *J. Biol. Chem.* **287**, 15523–15532
28. Gao, X. D., Nishikawa, A., and Dean, N. (2004) Physical interactions between the Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticulum. *Glycobiology* **14**, 559–570
29. Noffz, C., Keppler-Ross, S., and Dean, N. (2009) Hetero-oligomeric interactions between early glycosyltransferases of the dolichol cycle. *Glycobiology* **19**, 472–478
30. Vleugels, W., Haeuptle, M. A., Ng, B. G., Michalski, J. C., Battini, R., Dionisi-Vici, C., Ludman, M. D., Jaeken, J., Foulquier, F., Freeze, H. H., Matthijs, G., and Hennot, T. (2009) RFT1 deficiency in three novel CDG patients. *Hum. Mutat.* **30**, 1428–1434
31. Anand, M., Rush, J. S., Ray, S., Doucey, M. A., Weik, J., Ware, F. E., Hofsteenge, J., Waechter, C. J., and Lehrman, M. A. (2001) Requirement of the *Lec35* gene for all known classes of monosaccharide-P-dolichol-dependent glycosyltransferase reactions in mammals. *Mol. Biol. Cell* **12**, 487–501
32. Schenk, B., Imbach, T., Frank, C. G., Grubenmann, C. E., Raymond, G. V., Hurvitz, H., Korn-Lubetzki, I., Revel-Vik, S., Raas-Rotschild, A., Luder, A. S., Jaeken, J., Berger, E. G., Matthijs, G., Hennot, T., and Aebi, M. (2001) MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. *J. Clin. Invest.* **108**, 1687–1695
33. Gao, N., Shang, J., and Lehrman, M. A. (2005) Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis: implications for extracellular glucose and intracellular mannose 6-phosphate. *J. Biol. Chem.* **280**, 17901–17909
34. Manthri, S., Güther, M. L., Izquierdo, L., Acosta-Serrano, A., and Ferguson, M. A. (2008) Deletion of the *TbALG3* gene demonstrates site-specific N-glycosylation and N-glycan processing in *Trypanosoma brucei*. *Glycobiology* **18**, 367–383
35. Wassler, M., and Fries, E. (1993) Proteolytic cleavage of haptoglobin occurs in a subcompartment of the endoplasmic reticulum: evidence from membrane fusion *in vitro*. *J. Cell Biol.* **123**, 285–291
36. Kim, Y. J., Guzman-Hernandez, M. L., and Balla, T. (2011) A highly dynamic ER-derived phosphatidylinositol-synthesizing organelle supplies phosphoinositides to cellular membranes. *Dev. Cell* **21**, 813–824